US 2023/0149326 A1 · PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MUSCULAR WEAKNESS-RELATED DISEASES COMPRISING ALVERINE, 4-HYDROXY ALVERINE, DERIVATIVE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

Abstract

A pharmaceutical or food composition including alverine, 4-hydroxy alverine, a derivative thereof, or a salt thereof and their uses are disclosed. The composition is useful for preventing, alleviating, or treating muscular weakness-related diseases. When myoblasts are treated with the alverine, 4-hydroxy alverine, derivative thereof, or salt thereof, differentiation into myotubes is promoted. Therefore, the alverine, 4-hydroxy alverine, derivative thereof, or salt thereof can be effectively used in the promotion of differentiation of myoblasts and the prevention, alleviation, or treatment of muscular weakness-related diseases.

Claims20

Dependent claims

A compound of Formula 1 or a salt thereof:

I in Formula 1,
R1, R2, R4, and R5 are each independently hydrogen, halogen, —CF3, hydroxy, cyano, C1-10 alkyl, C1-10 alkoxy, C1-4 haloalkyl, C1-10 haloalkoxy, C2-4 alkenyl, C2-4 alkynyl, —NHRa, —NHC(═O)Rb, —NHC(═O)NHRc, amino-C1-10 alkoxy, C1-10 alkenyloxy, or C6-10 aryl-C1-10 alkoxy,
R3 is C1-10 alkyl, C2-12 alkenyl, C1-4 haloalkyl, C2-4 alkenyl, or C2-4 alkynyl,
Ra to Rc are each independently hydrogen, C1-6 alkyl, C1-6 alkoxy, C1-4 haloalkyl, C2-4 alkenyl, C2-4 alkynyl, or C6-10 aryl;
and
n and m are each independently an integer of 1 to 10.

3 more elements

Dependencies are inferred from the claim text.

Facts

Application

17/917,658Filed 9 Apr 2021

Priority

KR 10-2020-00434819 Apr 2020

Published

18 May 2023

Term ends

Not estimatedThe source records don’t support an estimate.

Classification21 codes

A23L 33/10
Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof: using additives
A61K 31/135
Amines: having aromatic rings , e.g. ketamine, nortriptyline
A61K 9/0056
Mouth and digestive tract, i.e. intraoral and peroral administration: mouth soluble or dispersible forms; Suckable, eatable, chewable coherent…
A61K 31/137
Having aromatic rings , e.g. ketamine, nortriptyline: arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone

Pharmaceutical composition for preventing or treating muscular weakness-related diseases comprising alverine, 4-hydroxy alverine, derivative thereof, or pharmaceutically acceptable salt thereof

Life of this patent

Pharmaceutical composition for preventing or treating muscular weakness-related diseases comprising alverine, 4-hydroxy alverine, derivative thereof, or pharmaceutically acceptable salt thereof

Life of this patent

Abstract

Claims20